SANA Files 8-K for Regulation FD Disclosure & Exhibits

Ticker: SANA · Form: 8-K · Filed: 2024-01-09T00:00:00.000Z

Sentiment: neutral

Topics: regulation-fd, compliance, exhibits

TL;DR

**SANA just filed a routine 8-K for disclosure and exhibits, nothing major.**

AI Summary

Sana Biotechnology, Inc. filed an 8-K on January 9, 2024, to disclose information under Regulation FD and to file financial statements and exhibits. This filing indicates that the company is adhering to its disclosure obligations, specifically regarding its Common Stock, $0.0001 par value per share, which is traded on The Nasdaq Global Select Market under the symbol SANA. For investors, this matters because it confirms Sana Biotechnology's ongoing compliance with SEC regulations, providing transparency and ensuring that all material information is being disseminated appropriately, which is crucial for informed investment decisions.

Why It Matters

This filing confirms Sana Biotechnology's commitment to transparency and regulatory compliance, which is essential for maintaining investor trust and a stable trading environment.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure filing and does not indicate any new material risks or changes to the company's operations.

Analyst Insight

Investors should view this as a routine compliance filing, confirming Sana Biotechnology's adherence to SEC disclosure requirements. No immediate action is suggested based solely on this administrative filing.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of Sana Biotechnology, Inc.'s 8-K filing dated January 9, 2024?

The 8-K filing by Sana Biotechnology, Inc. on January 9, 2024, serves to disclose information under Regulation FD and to file financial statements and exhibits, as stated in the 'ITEM INFORMATION' section of the filing.

On which stock exchange is Sana Biotechnology, Inc.'s Common Stock registered?

Sana Biotechnology, Inc.'s Common Stock, with a $0.0001 par value per share, is registered on The Nasdaq Global Select Market, as indicated under 'Securities registered pursuant to Section 12(b) of the Act'.

What is the trading symbol for Sana Biotechnology, Inc. on The Nasdaq Global Select Market?

The trading symbol for Sana Biotechnology, Inc.'s Common Stock on The Nasdaq Global Select Market is SANA, as specified in the 'Securities registered pursuant to Section 12(b) of the Act' table.

What is the earliest event reported date for this 8-K filing?

The date of the earliest event reported in this 8-K filing is January 9, 2024, as stated under 'Date of Report (Date of earliest event reported): January 9, 2024'.

What is the business address and phone number of Sana Biotechnology, Inc. as listed in the filing?

Sana Biotechnology, Inc.'s business address is 188 East Blaine Street, Suite 400, Seattle, Washington 98102, and its telephone number is (206) 701-7914, according to the 'BUSINESS ADDRESS' and 'Registrant’s telephone number' sections.

Filing Stats: 660 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2024-01-09 09:00:57

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure. Sana Biotechnology, Inc. (the "Company") intends to discuss an updated corporate presentation (the "Corporate Presentation") at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. A copy of the Corporate Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and is incorporated by reference herein. By furnishing the information in this Item 7.01 of this Current Report, including Exhibit 99.1, the Company makes no admission as to the materiality of such information. The information contained herein is intended to be considered in the context of the Company's filings with the U.S. Securities and Exchange Commission (the "SEC") and other public announcements that the Company makes, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the Corporate Presentation, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure. In accordance with General Instruction B.2 of Form 8-K, the information furnished with this Current Report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01

Item 9.01

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits See the Exhibit Index below, which is incorporated by reference herein. EXHIBIT INDEX Exhibit Number Description 99.1 Corporate Presentation dated January 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Sana Biotechnology, Inc. Date: January 9, 2024 By: /s/ Bernard J. Cassidy Bernard J. Cassidy Executive Vice President and General Counsel 2

View on Read The Filing